KD2 396
Alternative Names: KD2-396; Pentavalent vaccine - KM BiologicsLatest Information Update: 23 Nov 2023
At a glance
- Originator Kaketsuken
- Developer KM Biologics
- Class Bacterial vaccines; Haemophilus vaccines; Hepatitis B vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 23 Nov 2023 Phase-II clinical trials in Diphtheria (Prevention) in Japan (SC), before November 2023 (Meiji Seika Pharma pipeline, November 2023)
- 23 Nov 2023 Phase-II clinical trials in Haemophilus infections (Prevention) in Japan (SC), before November 2023 (Meiji Seika Pharma pipeline, November 2023)
- 23 Nov 2023 Phase-II clinical trials in Hepatitis B (Prevention) in Japan (SC), before November 2023 (Meiji Seika Pharma pipeline, November 2023)